Eosinophilic Gastritis (Eosinophilic gastroenteritis)

1. Comprehensive Executive Overview

Eosinophilic Gastritis (EG) is a rare, chronic inflammatory condition characterized by the abnormal infiltration of eosinophils—a type of white blood cell—into the mucosal, muscular, or serosal layers of the stomach wall. Classified under the broader umbrella of Eosinophilic Gastrointestinal Disorders (EGIDs), EG represents a complex immunological state where the body’s defense system overreacts to specific triggers.

Unlike transient inflammation, Eosinophilic Gastritis is a persistent, progressive disease that can lead to significant gastric dysfunction, tissue damage, and malabsorption. While its prevalence is difficult to estimate due to underdiagnosis, it is increasingly recognized in both pediatric and adult populations. Understanding this condition requires a multidisciplinary approach involving gastroenterologists, immunologists, and dietitians. The ICD-10 code for this condition is K52.81, which helps clinicians standardize care and insurance billing.

2. Detailed Pathophysiology, Etiology, and Risk Factors

The Pathophysiological Mechanism

The hallmark of Eosinophilic Gastritis is the massive recruitment of eosinophils into the gastric tissue. Under physiological conditions, eosinophils are present in the gastrointestinal tract but are notably absent from the esophagus and exist in low, controlled numbers in the stomach. In EG, this homeostatic balance is disrupted.

The process is generally mediated by Type 2 helper T-cell (Th2) immune responses. When an allergen or unknown stimulus interacts with the gastric mucosa, it triggers the release of pro-inflammatory cytokines, specifically Interleukin-5 (IL-5), Interleukin-4 (IL-4), and Interleukin-13 (IL-13). These cytokines drive the maturation, activation, and survival of eosinophils. Once these cells infiltrate the stomach tissue, they release toxic granular proteins, such as Major Basic Protein (MBP) and Eosinophil Peroxidase, which cause local tissue necrosis, mucosal erosions, and fibrosis.

Etiology and Risk Factors

The etiology of EG remains multifactorial, involving a complex interplay between genetics and the environment.

• Atopic Predisposition: A large percentage of patients with EG have a history of other atopic conditions, including asthma, allergic rhinitis, eczema, or food allergies.
• Genetic Factors: Genome-wide association studies have identified potential genetic markers that may predispose individuals to hyper-responsive eosinophilic activity.
• Environmental Triggers: Food antigens are the most commonly cited drivers. Common triggers include dairy, wheat, soy, eggs, and nuts, though the specific triggers vary significantly between patients.
• Microbiome Dysbiosis: Emerging research suggests that alterations in the gastric microbiota may play a role in initiating or exacerbating the inflammatory response.

3. Signs, Symptoms, and Clinical Presentation

The clinical presentation of Eosinophilic Gastritis is highly variable, largely depending on which layer of the stomach wall is predominantly affected (mucosal, muscular, or serosal).

Clinical Classifications based on Depth

1. Mucosal Disease: This is the most common form. It primarily causes epithelial damage, leading to abdominal pain, nausea, vomiting, early satiety, and weight loss. Iron-deficiency anemia is common due to chronic occult blood loss.
2. Muscularis Disease: Infiltration of the muscular layer leads to thickening of the stomach wall, resulting in gastric outlet obstruction, dysmotility, and severe post-prandial vomiting.
3. Serosal Disease: The rarest and most severe form. Eosinophilic ascites (fluid accumulation in the abdomen) is the hallmark symptom, often accompanied by high peripheral eosinophilia.

Common Symptomatology

• Epigastric Pain: Often burning or cramping in nature.
• Post-prandial Distress: Exacerbation of symptoms shortly after eating.
• Dyspepsia: Chronic indigestion that fails to respond to standard PPI therapy.
• Systemic Signs: Unexplained weight loss, fatigue, and lethargy.

4. Standard Diagnostic Evaluation & Workup

Diagnosing Eosinophilic Gastritis requires a high index of suspicion, as symptoms often mimic common issues like GERD or functional dyspepsia.

The Diagnostic Gold Standard

The diagnosis is strictly histological. An endoscopic examination is mandatory. During the procedure, the gastroenterologist must perform multiple biopsies from both the antrum and the corpus of the stomach.

• Biopsy Threshold: The current clinical standard is the identification of >30 eosinophils per high-power field (HPF) in at least 5 different HPFs.
• Endoscopic Appearance: Findings may include erythema, friability, ulcerations, nodules, or thickened gastric folds. However, it is important to note that the stomach can appear endoscopically normal in some cases of EG.

Laboratory Assays

• Complete Blood Count (CBC): To assess for peripheral eosinophilia. Note that many patients with isolated EG have normal peripheral blood counts.
• Serum Albumin: Often low in patients with protein-losing gastropathy associated with EG.
• IgE Levels: Total and specific IgE testing may be performed to screen for potential food triggers.

Imaging

• CT/MRI Scans: Useful for identifying gastric wall thickening or complications like ascites (in serosal disease).
• Endoscopic Ultrasound (EUS): Provides superior visualization of the gastric wall layers to determine the depth of infiltration.

5. Therapeutic Interventions

Management is typically staged, starting with conservative dietary changes and escalating to pharmacotherapy.

Dietary Management

• Elimination Diet: The most effective non-pharmacological approach. Patients undergo a strict exclusion of the six most common food allergens (SFED - Six-Food Elimination Diet). Reintroduction is done systematically to identify the culprit.
• Elemental Diet: Reserved for severe, refractory cases where patients are placed on an amino acid-based formula exclusively for several weeks to allow the mucosa to heal completely.

Pharmacotherapy

1. Proton Pump Inhibitors (PPIs): Often the first-line treatment. Some patients respond to PPIs due to their anti-inflammatory properties, a condition sometimes termed PPI-responsive eosinophilic gastric symptoms.
2. Corticosteroids: Systemic steroids (e.g., Prednisone) are highly effective for acute flares but are generally avoided for long-term use due to side-effect profiles.
3. Topical/Swallowed Steroids: Budesonide or Fluticasone may be used to provide localized anti-inflammatory effects with fewer systemic side effects.
4. Biologics: Emerging research into anti-IL-5 monoclonal antibodies (like Mepolizumab or Benralizumab) has shown promise for patients who are refractory to standard therapies.

Surgical Intervention

Surgery is rarely indicated and is reserved for complications such as gastric outlet obstruction or perforation that do not respond to medical management.

6. FAQ: Frequently Asked Questions

1. Is Eosinophilic Gastritis a form of cancer?
No, Eosinophilic Gastritis is an inflammatory condition, not a malignancy. However, it requires careful monitoring to ensure symptoms are not confused with gastric lymphoma.

2. Can I cure Eosinophilic Gastritis with diet alone?
Many patients achieve remission through dietary elimination. However, "cure" is a strong word; the condition is chronic, and symptoms may return if triggers are reintroduced.

3. Is there a genetic test for EG?
Currently, there is no standardized genetic test for EG. It is considered a complex disease influenced by multiple genes.

4. How long does it take to see results after changing my diet?
Most patients notice an improvement in symptoms within 2 to 4 weeks of strict adherence to an elimination diet.

5. Are there long-term complications if left untreated?
Yes, untreated EG can lead to chronic fibrosis, permanent tissue damage, malabsorption, and severe weight loss.

6. Can stress cause Eosinophilic Gastritis?
While stress does not cause the disease, it can exacerbate the perception of symptoms and trigger flare-ups in patients with an existing diagnosis.

7. Is peripheral eosinophilia always present in EG?
No. Peripheral eosinophilia is only present in about 50% of patients with EG. A normal blood test does not rule out the condition.

8. What is the difference between EG and Eosinophilic Esophagitis (EoE)?
EoE affects the esophagus and is more common, while EG affects the stomach. It is possible for a patient to have both, which is classified as Eosinophilic Gastroenteritis.

9. Will I need to be on medication for the rest of my life?
Not necessarily. Many patients successfully manage their condition through long-term dietary modification, potentially reducing or eliminating the need for daily medication.

10. What is the prognosis for patients with EG?
With proper diagnosis and adherence to treatment (dietary or medical), the long-term prognosis is excellent, and most patients lead normal, healthy lives.

Disclaimer: This guide is for educational purposes only and does not replace professional medical advice. Always consult with a board-certified gastroenterologist for diagnosis and treatment plans tailored to your specific clinical history.

Related Clinical Integration

In the management of Eosinophilic Gastritis, clinical intervention is typically bifurcated into pharmacological stabilization and diagnostic visualization. First-line therapy often involves systemic corticosteroids such as Prednisone / بريدنيزون 5 mg to effectively suppress the underlying eosinophilic infiltration and mitigate symptomatic inflammation. Concurrently, for patients requiring definitive histological confirmation or targeted therapeutic intervention for mucosal lesions, the use of a Gastroscope (GIF-1TQ260 - Therapeutic) / منظار المعدة (GIF-1TQ260 - علاجي) is essential, as it allows clinicians to perform precise biopsies and evaluate the extent of gastric involvement within our hospital’s specialized gastroenterology unit.